Ucb SA logo

UCB - Ucb SA News Story

€79.26 -1.7  -2.1%

Last Trade - 12/04/21

Sector
Healthcare
Size
Large Cap
Market Cap £13.28bn
Enterprise Value £14.23bn
Revenue £4.64bn
Position in Universe 58th / 847

BUZZ-European pharma: CS sees derating relative to other sectors

Wed 20th January, 2021 10:12am
** Credit Suisse has a less favourable view of the pharma
sector entering 2021 and names macro, politics, pricing,
disruption and positioning as key areas of concern
    ** The brokerage says pharma tends to be the worst
performing sector when the dollar weakens, and expects more
political pressure, especially from the incoming Biden
presidency in the U.S. 
    ** It notes that as earnings of companies from other sectors
got more severely hit by COVID-19, the historic sector
price-earnings ratio (PE) premium has declined for major pharma
companies    
    ** To reflect derating of the sector relative to the
European markets, CS trims target prices for Sanofi  SASY.PA ,
AstraZeneca  AZN.L , Novartis  NOVN.S , GSK  GSK.L , Grifols
 GRLS.MC  and Ipsen  IPN.PA  
    ** It raises PT on Bayer  BAYGn.DE , citing positive Ag
backdrop; on Lonza  LONN.S  and Merck  MRCG.DE  due to their
growth potential, and on biotech/specialty pharma companies UCB
 UCB.BR , Almirall  ALM.MC , Recordati  RECI.MI , Orion
 ORNBV.HE  and Lundbeck  LUN.CO      
    ** The brokerage downgrades GSK  GSK.L  to "underperform"
from "neutral", citing multiple near-term and strategic
challenges and hence limited upside versus peers
    ** It cuts Novo Nordisk  NOVOb.CO  to "neutral" from
"outperform" as following a strong performance over 2020, the
risk/reward is more balanced with 2021 unlikely to be a
transformational year



 ((marta.frackowiak@thomsonreuters.com))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.